Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition
{{output}}
Direct Oral Anticoagulants (DOACs) have revolutionized the treatment of thromboembolic disorders, offering targeted, effective, and safer alternatives to traditional anticoagulants like heparins and vitamin K antagonists (VKAs). Despite their benefits, DOACs h... ...